Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Xenetic Biosciences Q1 EPS $(0.59) Beats $(0.72) Estimate, Sales $593.26K Miss $670.00K Estimate

Author: Benzinga Newsdesk | May 13, 2025 04:58pm
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.72) by 18.06 percent. This is a 24.36 percent increase over losses of $(0.78) per share from the same period last year. The company reported quarterly sales of $593.26 thousand which missed the analyst consensus estimate of $670.00 thousand by 11.45 percent. This is a 16.14 percent increase over sales of $510.82 thousand the same period last year.

Posted In: XBIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist